Related references
Note: Only part of the references are listed.A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
George Z. Retsch-Bogart et al.
PEDIATRIC PULMONOLOGY (2008)
Cystic fibrosis pulmonary guidelines - Chronic medications for maintenance of lung health
Patrick A. Flume et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Clinical trials in cystic fibrosis
Gerd Doering et al.
JOURNAL OF CYSTIC FIBROSIS (2007)
Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial
A. Clement et al.
THORAX (2006)
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
Ronald L. Gibson et al.
PEDIATRIC PULMONOLOGY (2006)
Development and validation of the cystic fibrosis questionnaire in the United States - A health-related quality-of-life measure for cystic fibrosis
AL Quittner et al.
CHEST (2005)
Pathophysiology and management of pulmonary infections in cystic fibrosis
RL Gibson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients
B Henry et al.
QUALITY OF LIFE RESEARCH (2003)
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis
AC Modi et al.
JOURNAL OF PEDIATRIC PSYCHOLOGY (2003)
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
ME Hodson et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
RB Moss
CHEST (2002)
Defining a pulmonary exacerbation in cystic fibrosis
M Rosenfeld et al.
JOURNAL OF PEDIATRICS (2001)
Administration of aerosolized antibiotics in cystic fibrosis patients
RB Moss
CHEST (2001)
Share Paper
